2023NICE医疗技术创新简报：用于评估注意力缺陷多动障碍(ADHD)的QbTest[MIB318]

NICENational Institute forHealth and Care ExcellenceNICE9adviceQbTest for the assessment ofattention deficit hyperactivitydisorder (ADHD)Medtech innovation briefingPublished:7 March 2023www.nice.org.uk/guidance/mib318SummaryThe technology described in this briefing is QbTest.It is used to help assess attentiondeficit hyperactivity disorder(ADHD)and to evaluate different treatments for peoplewith ADHD when combined with the standard care clinician assessment.The innovative aspects are that it combines a continuous performance test with anobjective and standardised measure of motor(physical)activity.The innovation of thistechnology is its objectivity compared with potentially subjective neurodevelopmentalassessments.The intended place in therapy would be for people who have been referred for anADHD assessment.It would be used with the assessments that make up standard careand cannot be used as a separate,independent diagnostic assessment for ADHD.QbTest is also indicated for use as an aid in evaluating treatment effect for ADHD.NICE 2023.All rights reserved.Subject to Notice of rights (https://www.nice.org.uk/terms-and-Page 1 ofconditions#notice-of-rights).16